Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Polatuzumab vedotin-piiq
Trade Name Polivy
Synonyms DCDS4501A
Drug Descriptions

Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody against B-cell antigen receptor complex-associated protein beta chain (CD79B) linked to monomethyl auristatin E (MMAE), which may deliver the cytotoxic MMAE to tumor cells over expressing CD798 (PMID: 26194424). Polivy (polatuzumab vedotin-piiq) in combination with Treanda (bendamustine) and Rituxan (rituximab) is FDA approved for use in patients with relapsed or refractory diffuse large B-cell lymphoma (FDA.gov).

DrugClasses

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq Atezolizumab Obinutuzumab Polatuzumab vedotin-piiq 0 1
Bendamustine + Polatuzumab vedotin-piiq + Rituximab Bendamustine Polatuzumab vedotin-piiq Rituximab 1 1
BTCT4465A + Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone BTCT4465A Cyclophosphamide Doxorubicin Polatuzumab vedotin-piiq Prednisone 0 1
BTCT4465A + Polatuzumab vedotin-piiq BTCT4465A Polatuzumab vedotin-piiq 0 1
Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide Doxorubicin Etoposide Filgrastim Polatuzumab vedotin-piiq Prednisone Rituximab 0 1
Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide Doxorubicin Polatuzumab vedotin-piiq Prednisone Rituximab 0 1
Gemcitabine + Oxaliplatin + Polatuzumab vedotin-piiq + Rituximab Gemcitabine Oxaliplatin Polatuzumab vedotin-piiq Rituximab 0 1
Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq Lenalidomide Obinutuzumab Polatuzumab vedotin-piiq 0 1
Obinutuzumab + Polatuzumab vedotin-piiq Obinutuzumab Polatuzumab vedotin-piiq 0 1
Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Obinutuzumab Polatuzumab vedotin-piiq Rituximab 0 1
Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax Obinutuzumab Polatuzumab vedotin-piiq Venetoclax 0 1
Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab Pinatuzumab Vedotin Polatuzumab vedotin-piiq Rituximab 0 1
Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq 0 3


Additional content available in CKB BOOST